Mitsubishi UFJ Trust & Banking Corp Has $5.83 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mitsubishi UFJ Trust & Banking Corp grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 20.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 47,325 shares of the specialty pharmaceutical company's stock after purchasing an additional 7,963 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.08% of Jazz Pharmaceuticals worth $5,828,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. CIBC Asset Management Inc raised its holdings in Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock valued at $243,000 after buying an additional 97 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after acquiring an additional 129 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares in the last quarter. Waterfront Wealth Inc. lifted its holdings in Jazz Pharmaceuticals by 1.4% in the 4th quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company's stock worth $1,191,000 after purchasing an additional 137 shares during the last quarter. Finally, Ellsworth Advisors LLC boosted its position in Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock worth $4,675,000 after purchasing an additional 149 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded down $10.78 during trading hours on Friday, hitting $110.04. The stock had a trading volume of 2,171,302 shares, compared to its average volume of 754,628. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The company has a market cap of $6.68 billion, a PE ratio of 15.50, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a 50-day moving average of $132.27 and a two-hundred day moving average of $122.91. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent analyst reports. Morgan Stanley reissued an "overweight" rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Needham & Company LLC reissued a "buy" rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their price target for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $187.71.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the sale, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,023,305 over the last ninety days. 4.20% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.